Icon Plc (NASDAQ:ICLR – Get Free Report) CAO Emer Lyons sold 272 shares of the business’s stock in a transaction dated Friday, October 23rd. The stock was sold at an average price of $182.37, for a total transaction of $49,604.64. Following the sale, the chief accounting officer owned 990 shares in the company, valued at $180,546.30. This trade represents a 21.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Icon Stock Performance
Shares of NASDAQ:ICLR opened at $185.27 on Monday. The company has a 50 day moving average of $168.77 and a 200-day moving average of $151.89. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.23. The firm has a market cap of $14.19 billion, a P/E ratio of 43.49, a P/E/G ratio of 11.98 and a beta of 1.24. Icon Plc has a twelve month low of $66.57 and a twelve month high of $203.91.
Icon (NASDAQ:ICLR – Get Free Report) last announced its earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, topping the consensus estimate of $2.55 by $0.01. The firm had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.26 earnings per share. As a group, analysts anticipate that Icon Plc will post 9.55 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Icon
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Polianta Ltd acquired a new position in shares of Icon in the 2nd quarter valued at $1,876,000. Maple Rock Capital Partners Inc. raised its holdings in Icon by 257.8% during the 2nd quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company’s stock worth $208,383,000 after buying an additional 864,300 shares during the period. Royal Bank of Canada raised its holdings in Icon by 68.0% during the 1st quarter. Royal Bank of Canada now owns 153,728 shares of the medical research company’s stock worth $17,011,000 after buying an additional 62,225 shares during the period. Trinity Street Asset Management LLP raised its holdings in Icon by 27.1% during the 2nd quarter. Trinity Street Asset Management LLP now owns 1,535,462 shares of the medical research company’s stock worth $266,725,000 after buying an additional 327,314 shares during the period. Finally, VELA Investment Management LLC lifted its stake in Icon by 511.4% during the second quarter. VELA Investment Management LLC now owns 12,192 shares of the medical research company’s stock valued at $2,118,000 after buying an additional 10,198 shares in the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
ICLR has been the topic of a number of research reports. Robert W. Baird set a $194.00 price objective on Icon in a research note on Friday, July 31st. William Blair raised Icon to a “strong-buy” rating in a research note on Thursday, July 30th. Citigroup lowered their target price on Icon from $180.00 to $175.00 and set a “neutral” rating on the stock in a report on Friday, September 18th. UBS Group began coverage on shares of Icon in a research report on Wednesday, September 30th. They issued a “neutral” rating and a $195.00 price target on the stock. Finally, Truist Financial reissued a “buy” rating and issued a $209.00 price target (up from $207.00) on shares of Icon in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Icon has a consensus rating of “Hold” and a consensus price target of $174.73.
Check Out Our Latest Stock Analysis on ICLR
Icon Company Profile
ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.
Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.
Read More
- Five stocks we like better than Icon
- Broadcom’s AI Chip Business Is Booming, But Alphabet’s Strategy Highlights 2 Key Risks
- Amazon’s $350 Price Target Faces a Big Earnings Test
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.
